SCHEMBL4034444

SCHEMBL4034444

COc1ccc2cc(NC(=O)c3ccccc3NCc3ccc(C#N)nc3)c(=O)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MAPT P10636 5/20 0.47
RAB9A P51151 6/20 0.46
MAOB P27338 5/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 5/20 0.46
GAA P10253 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ACHE P22303 1/20 0.46
HDAC1 Q13547 1/20 0.45
MAOA P21397 4/20 0.45
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 3/20 0.43
GLA P06280 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037715 0.89 NPC1 (0.49) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4038456 0.88 NPC1 (0.50) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL6542788 0.87 APP (0.49) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4038457 0.86 NPC1 (0.49) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4036529 0.86 HDAC1 (0.46) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4033398 0.82 NPC1 (0.49) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4038209 0.81 NPC1 (0.50) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4038213 0.80 NPC1 (0.49) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4040918 0.79 NPC1 (0.46) NPC1RXFP1MAPTRAB9AMAOB
SCHEMBL4037662 0.74 NPC1 (0.60) NPC1RXFP1MAPTRAB9AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 EP disclosed
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed
EP-1392680-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2004-03-03 EP disclosed
WO-2002090352-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 NPC1 4864/4885RXFP1 558/4885MAPT 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.